APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

News > Business News

Audio By Carbonatix

7:56 AM on Tuesday, March 31

The Associated Press

NEW YORK--(BUSINESS WIRE)--Mar 31, 2026--

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE.

Halper Sadeh encourages Apellis shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected].

The investigation concerns whether Apellis and its board of directors violated the federal securities laws and/or breached their fiduciary duties by failing to: (1) obtain the best possible price for Apellis shareholders; (2) conduct a fair sales process free of any conflicts of interests; and (3) disclose all material information for Apellis shareholders to evaluate the transaction.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260331407307/en/

CONTACT: Halper Sadeh LLC

One World Trade Center

85th Floor

New York, NY 10007

Daniel Sadeh, Esq.

Zachary Halper, Esq.

(212) 763-0060

[email protected]

https://www.halpersadeh.com

KEYWORD: NEW YORK UNITED STATES NORTH AMERICA